Wall Street Analysts Are Bullish on Top Healthcare Picks
Analysts at Jefferies, Evercore ISI, and BMO Capital maintained Buy ratings on Ascendis Pharma (ASND), Alnylam Pharma (ALNY), and Crispr Therapeutics (CRSP), with price targets of $330, $325.20, and $76 respectively. The consensus ratings are Strong Buy for ASND and ALNY, and Moderate Buy for CRSP, with average price targets indicating potential upside.
How this was made
The 30-second read
Why it matters
The upgrades may trigger short‑term buying pressure in each stock.
Market read
Analyst upgrades provide new actionable insight for three biotech stocks.
What to watch
No new clinical data; upgrades rely on expectations.
Background
Three analysts issued fresh Buy ratings and higher price targets for Ascendis Pharma, Alnylam Pharma, and Crispr Therapeutics.
Ticker impact
Jefferies maintained a Buy rating on Ascendis Pharma and set a new price target of $330.
Potential upside of ~30% from current levels.
Buy rating and higher target suggest near‑term buying interest.
Evercore ISI maintained a Buy rating on Alnylam Pharma and raised the price target to $325.20.
Potential upside of ~35% from current levels.
Buy rating and higher target indicate renewed confidence.
Evercore ISI maintained a Buy rating on Crispr Therapeutics and set a price target of $76.
Potential upside of ~25% from current levels.
Buy rating and target suggest positive sentiment.
Market effects
Analyst bullishness may lift broader healthcare biotech sentiment.
US biotech sector may see modest inflows.
Limited to investors tracking biotech equities.
Counterpoint
Ratings could be premature if upcoming trial data disappoints.
Key entities
- AnalystJefferies
Issued Buy rating for Ascendis Pharma.
- AnalystEvercore ISI
Issued Buy ratings for Alnylam Pharma and Crispr Therapeutics.
